The following is a current chart of disease modifying therapies approved for the treatment of multiple sclerosis, as of November 2020. Reviewed by Rocky Mountain MS Center Medical Director Dr. Timothy…
Read More
EDITOR’S NOTE: Information contained in this article is current as of the time of printing, Nov. 25, 2020. Despite months of precautions, warnings and official guidelines, the COVID-19 pandemic is…
A Lifelong Practice for Coping with Stress and Anxiety As we reflect on the past year, some words and emotions are likely to surface for many of us right away:…
A Look at Current Research Priorities at the Rocky Mountain MS Center at University of Colorado The Rocky Mountain MS Center at University of Colorado is the home of one…
It’s no secret that many of the most commonly-prescribed MS treatments can be expensive, making access to them difficult for some people living with MS. Understanding this, many pharmaceutical companies…
Individualizing treatment according to a patient’s risk profile starting with high-efficacy treatments helps prevent irreversible brain and spinal cord damage, thus leading to better outcomes. First Line: Natalizumab (Tysabri) in JCV…
A timeline of the FDA approval of various disease modifying therapies for multiple sclerosis. 1993 Interferon β-1b SQ (Betaseron®) 1996 Interferon β-1a IM (Avonex® ) 1996 Glatiramer acetate SQ (GA –…
The Rocky Mountain MS Center and our partners at the Rocky Mountain MS Center at University of Colorado advocate for a fundamental philosophy of maximizing lifelong brain health through early…